There is no one-size-fits-all template for getting a molecular diagnostic (MDx) assay to market. In addition to the fundamental scientific problems, companies may encounter a range of challenges around supply chain management, manufacturing, and compliance.
Most of these challenges can be overcome, with some even being able to be prevented. As a veteran board member and storied investor in MDx companies, Harry Glorikian has observed diagnostic success and failure.
Glorikian is presently a general partner at Scientia Ventures. He outlined some of these lessons regarding success in his book, titled “Commercializing Novel IVDs: A Comprehensive Manual for Success”. This book has become a respected industry resource, with one of his key messages being that companies must have a macro plan in place from the very start.
Glorikian shares some tips in this interview regarding how early-stage companies can identify and select the best suppliers, considering the maximization of the relationship and mitigation of risk.
Get the competitive advantage.
Download the full interview
About LGC Biosearch Technologies
Together, we help you advance.
Whether you’re using marker-assisted selection to develop more nutritious and sustainable crops or developing the next generation of molecular diagnostic tests, clinical genomics assays, or novel oligo therapeutics, accurate and high-quality data is everything. And so is speed.
To help keep your mission-critical projects on target and moving quickly, LGC provides a large integrated portfolio of products and services to support your entire genomics workflow and help at every stage of your product development pipeline. From R&D through to large-scale commercialization, our products and services scale up when you do.
Watch the video to see how our unified genomics portfolio helps you discover more, speeding up your work to improve the human condition.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.